Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot, Ewout Willem Steyerberg, Mark I. van Berge Henegouwen, Bas P. L. Wijnhoven, Dick J. Richel, Grard A. P. Nieuwenhuijzen, Geke A.P. Hospers, Johannes J. Bonenkamp, Miguel A. Cuesta, Reinoud J. B. Blaisse, Olivier R. Busch, Fiebo J.W. ten Kate, G. J. M. Creemers, Cornelis J.A. Punt, John Theodorus Plukker, Henk M.W. Verheul, Ernst Jan Spillenaar Bilgen, Herman van Dekken, Maurice J.C. van der Sangen, Tom Rozema, Katharina Biermann, Jannet C. Beukema, Anna H.M. Piet, Caroline M. van Rij, Janny G. Reinders, H.W. Tilanus, Ate van der Gaast
New England Journal of Medicine · 2012 · 5,591 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Hagen, P. van, Hulshof, M. C., Lanschot, J. J. B. van, Steyerberg, E. W., Henegouwen, M. I. van B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J. B., Busch, O. R., Kate, F. J. ten, Creemers, G. J. M., Punt, C. J., Plukker, J. T., Verheul, H. M., Bilgen, E. J. S., … Gaast, A. van der. (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine, 366(22), 2074–2084. https://doi.org/10.1056/nejmoa1112088
In text: (Hagen et al., 2012)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population. METHODS: We randomly assigned patients with resectable tumors to receive surgery alone or weekly administration of carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), followed by surgery. RESULTS: From March 2004 through December 2008, we enrolled 368 patients, 366 of whom were included in the analysis: 275 (75%) had adenocarcinoma, 84 (23%) had squamous-cell carcinoma, and 7 (2%) had large-cell undifferentiated carcinoma. Of the 366 patients, 178 were randomly assigned to chemoradiotherapy followed by surgery, and 188 to surgery alone. The most common major hematologic toxic effects in the chemoradiotherapy-surgery group were leukopenia (6%) and neutropenia (2%); the most common major nonhematologic toxic effects were anorexia (5%) and fatigue (3%). Complete resection with no tumor within 1 mm of the resection margins (R0) was achieved in 92% of patients in the chemoradiotherapy-surgery group versus 69% in the surgery group (P<0.001). A pathological complete response was achieved in 47 of 161 patients (29%) who underwent resection after chemoradiotherapy. Postoperative complications were similar in the two treatment groups, and in-hospital mortality was 4% in both. Median overall survival was 49.4 months in the chemoradiotherapy-surgery group versus 24.0 months in the surgery group. Overall survival was significantly better in the chemoradiotherapy-surgery group (hazard ratio, 0.657; 95% confidence interval, 0.495 to 0.871; P=0.003). CONCLUSIONS: Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer. The regimen was associated with acceptable adverse-event rates. (Funded by the Dutch Cancer Foundation [KWF Kankerbestrijding]; Netherlands Trial Register number, NTR487.).
Related papers
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER22001
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989
- Comprehensive molecular characterization of gastric adenocarcinoma2014
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer2006
Metadata from OpenAlex (CC0). Citations are generated from the published record.